Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001–2011

Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996–2006

(2014) Silvia Alessi-Severini et al.   PSYCHIATRIC SERVICES

Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals

(2012) Rikje Ruiter et al.   DRUG SAFETY

Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

(2012) Stacie B. Dusetzina et al.   MEDICAL CARE

Trends in Antipsychotic Use in Dementia 1999-2007

(2011) Helen C. Kales et al.   ARCHIVES OF GENERAL PSYCHIATRY

Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis

(2011) Pauline Lockhart et al.   BRITISH JOURNAL OF GENERAL PRACTICE

The burden of psychotropic drug prescribing in people with dementia: a population database study

(2010) Bruce Guthrie et al.   AGE AND AGEING

Impact of FDA Black Box Advisory on Antipsychotic Medication Use

(2010) E. Ray Dorsey   ARCHIVES OF INTERNAL MEDICINE

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

(2009) Clive Ballard et al.   LANCET NEUROLOGY

Management of agitation and aggression associated with Alzheimer disease

(2009) Clive G. Ballard et al.   Nature Reviews Neurology

Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia

(2008) Paula A. Rochon   ARCHIVES OF INTERNAL MEDICINE

Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis

(2008) E. Valiyeva et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults

(2008) L. Y. Katz et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL